Clinical Trials Logo

Recurrent Implantation Failure clinical trials

View clinical trials related to Recurrent Implantation Failure.

Filter by:
  • None
  • Page 1

NCT ID: NCT03174964 Recruiting - Clinical trials for Recurrent Implantation Failure

Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure

Start date: July 20, 2016
Phase: Phase 2
Study type: Interventional

Infertility and miscarriage ordinary events in reproductive failure in humans, as are affected one couple in every six couples of reproductive age and abortion is including in approximately 15-20% of all pregnancies. Over the decades since the beginning of Assisted Reproductive Technology (ART) and in vitro fertilization (IVF) pregnancy rate still remains below 30% and Recurrent Implantation Failure in one of the most important limiting factor is the assisted reproductive techniques. According to studies conducted in recent years one of the most important mechanisms of implantation failure is maternal immune system because the fetus as an allograft toxic (Semi allograft) to the mother. Studies have demonstrated that ratio of Th1 to Th2 cells increase in maternal peripheral blood cells can be directly associated with implantation failure. It also increases the number of natural killer (NK) cells and Th17 cells and their cytokines in peripheral blood of mother and is also associated with an increased risk of infertility. Several studies have also shown that the fertile persons in compare to infertile have increased amount of Treg cells and inhibitory cytokines associated with it. The studies have shown that if patients are properly selected RIF and placed under appropriate immunotherapy approaches it will be seen a significant increase in fertility. In previous years, followed by the production of intravenous immunoglobulin (IVIg) and determine its effect on immune suppression, IVIg uses for the treatment of various diseases such as thrombocytopenic purpura, Guillain-Barre syndrome, Kawasaki disease and Myasthenia gravis. It is also valuable drug for the treatment of patients with infertility problems have also been used but still remains how well the drug and its mechanism of action are unknown. Probably one of the mechanisms of IVIg is its effect in suppressing the activity of NK cells. Likely IVIg cause to increase Cluster of Differentiation 94 (CD94) molecule as an inhibitor molecule on the NK cells and reduced the cytotoxic activity of NK cells. So because of reduce the cytotoxic activity of NK cells by IVIg in patients with RIF injection increases the likelihood of successful implantation. Previous studies have shown that the incidence of genetic abnormalities in children who have received immunosuppressive drugs such as IVIg like normal people and normal society. In this study we used IVIg before IVF to suppress the immune system in patients with immunological causes of RIF and the results will be compared with a control group that did not receive any type of drug.

NCT ID: NCT03161340 Recruiting - Clinical trials for Recurrent Implantation Failure

Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure

Start date: May 11, 2017
Phase: Phase 2
Study type: Interventional

Infertility and miscarriage ordinary events in reproductive failure in humans, as are affected one couple in every six couples of reproductive age and abortion is including in approximately 15-20% of all pregnancies. Over the decades since the beginning of Assisted Reproductive Technology (ART) and in vitro fertilization (IVF) pregnancy rate still remains below 30% and Recurrent Implantation Failure in one of the most important limiting factor is the assisted reproductive techniques. According to studies conducted in recent years one of the most important mechanisms of implantation failure is maternal immune system because the fetus as an allograft toxic (Semi allograft) to the mother. Studies have demonstrated that ratio of Th1 to Th2 cells increase in maternal peripheral blood cells can be directly associated with implantation failure. It also increases the number of natural killer (NK) cells and Th17 cells and their cytokines in peripheral blood of mother and is also associated with an increased risk of infertility. Several studies have also shown that the fertile persons in compare to infertile have increased amount of Treg cells and inhibitory cytokines associated with it. The studies have shown that if patients are properly selected RIF and placed under appropriate immunotherapy approaches it will be seen a significant increase in fertility. Among the factors affecting the performance of the immune system, small non-coding MicroRNA (miRNA) noted that the RNA of 19-22 nucleotides in length. MicroRNAs act by inhibiting expression of target genes can be linked to pregnancy and implantation process. Hence micro RNAs can be used as biomarkers for the detection, predicting pregnancy and even infertility treatment. Studies have shown that micro-RNAs in the endometrium are in dynamic changes during the menstrual cycle, reproductive system and implantation and diseases such as endometriosis, frequent miscarriage. MicroRNA-1229, miR-133b and miR-223 was proposed to select and review their changes before and after treatment with Rapamycin. Rapamycin is a macrolide fungus was identified about 40 years ago. Biochemical studies on primates led to the identification of molecules mammilian target of rapamycin (mToR) is the target molecule for Rapamycin. MToR molecules play a fundamental role in the regulation of cell metabolism, cell proliferation and mammalian cell response to environmental conditions and play a role in the process of cell growth and cell proliferation. While mTOR Complex 2 (mTORC2) play role in the survival and migration of cells. Rapamycin inhibits T lymphocyte proliferation through inhibit mToRc1 function. In this study, after we selected patients with RIF, according to immunologic disorders are treated with Rapamycin, a drug suppress the immune system is then put the result of treatment with immunological parameters as well as we have evaluated possible effects in success of the implantation and response to treatment.

NCT ID: NCT02752568 Not yet recruiting - Clinical trials for Recurrent Implantation Failure

Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure

Start date: May 2016
Phase: N/A
Study type: Interventional

300 recurrent implantation failure patients will be alternatively assigned to assisted hatching , endometrial scratch , and no treatment ,100 patients in each group

NCT ID: NCT01278706 Not yet recruiting - Infertility Clinical Trials

Endometrial Biopsy Protocol for In Vitro Fertilization (IVF)

Start date: January 2011
Phase: N/A
Study type: Interventional

Endometrial biopsy has been shown to improve IVF pregnancy and live birth rates. The optimal time of performing the biopsy is yet to be established. In this study, the investigators will compare different temporal timing of the biopsies with regards to the menstrual cycle and their affect on the success rates of the treatment.

NCT ID: NCT00750451 Completed - Infertility Clinical Trials

Low Molecular Weight Heparin in Recurrent Implantation Failure

Start date: January 2006
Phase: N/A
Study type: Interventional

Recurrent implantation failure is the failure to achieve a pregnancy after multiple attempts with in vitro fertilization treatment. The reason is usually obscure. Many empirical treatments have been offered without substantial evaluation. Heparin is thought to play a role in the embryo implantation process beyond its anticoagulation effects. The proposed study aims to assess the effectiveness and safety of empirical administration of low molecular weight heparin in patients undergoing a new IVF treatment cycle after multiple failed attempts.